Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the target of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 900 shares, an increase of 125.0% from the January 31st total of 400 shares. Based on an average daily trading volume, of 13,500 shares, the days-to-cover ratio is currently 0.1 days.

Scinai Immunotherapeutics Stock Performance

Shares of NASDAQ:SCNI remained flat at $3.54 during trading on Friday. 1,969 shares of the stock were exchanged, compared to its average volume of 14,584. The stock has a 50 day moving average of $3.47 and a 200-day moving average of $3.53. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.16 and a quick ratio of 1.16. Scinai Immunotherapeutics has a twelve month low of $2.23 and a twelve month high of $8.92. The firm has a market cap of $3.02 million, a P/E ratio of -0.01 and a beta of 2.37.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.